Summit inks $58M development deal

Summit Corporation will pocket a $7 million upfront fee in the form of an equity investment from a new licensing pact with BioMarin Pharmaceutical. BioMarin inked a worldwide licensing agreement for Summit's preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat the fatal genetic disorder Duchenne muscular dystrophy. Summit also stands to gain up to $51 million in milestones. Release

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.